GlassScriptPhysician profile
John Russomanno
NPI 1023112596
$17,554.81
in general payments reported to CMS, 2019-2025
48 companies · $3,885 in 2025
The $3,885 reported for 2025 was more than what 86% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,025 · 2020: $660 · 2021: $2,540 · 2022: $2,524 · 2023: $2,837 · 2024: $3,083 · 2025: $3,885.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,804 · Education: $1.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,804.37 |
| Education | $1.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $5,294.64 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Astrazeneca Pharmaceuticals LP | $3,517.55 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,109.32 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Novartis Pharmaceuticals Corporation | $810.15 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $584.77 | 2019-2025 | Dupixent |
| Amgen INC. | $520.80 | 2022-2025 | Tezspire, Tavneos |
| Harmony Biosciences LLC | $499.24 | 2021-2025 | Wakix |
| Mallinckrodt Hospital Products INC. | $475.52 | 2020-2025 | Acthar |
| Takeda Pharmaceuticals U.S.A., INC. | $469.34 | 2022-2025 | Glassia, Hyqvia |
| Actelion Pharmaceuticals US, INC. | $310.90 | 2019-2025 | Opsumit, Uptravi, Opsynvi |
| Mylan Specialty L.P. | $302.60 | 2019-2023 | Yupelri |
| Verona Pharma, INC. | $285.28 | 2025 | Ohtuvayre |
| Viatris Specialty LLC | $284.24 | 2025 | Yupelri |
| Genentech USA, INC. | $283.58 | 2019-2024 | Xolair |
| Janssen Pharmaceuticals, INC | $271.96 | 2019-2022 |
Show all 48 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $242.69 | 2021-2025 | Arikayce, Brinsupri |
| Genzyme Corporation | $214.19 | 2019-2024 | |
| Baxter Healthcare | $208.45 | 2022-2024 | Hillrom - Monarch Airway Clearance System, Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Philips North America LLC | $203.58 | 2021-2025 | (Ak6) Vest Therapy, Vest Therapy Und, (O58) Sleep Respiratory Care Und |
| Pfizer INC. | $193.22 | 2019-2024 | |
| Jazz Pharmaceuticals INC. | $167.59 | 2021-2024 | |
| Axsome Therapeutics, INC. | $146.20 | 2022-2025 | Sunosi |
| Covis Pharma Gmbh | $142.49 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $137.66 | 2019 | |
| Electromed, INC. | $103.66 | 2021-2025 | Smartvest |
| Merck Sharp & Dohme LLC | $80.84 | 2019-2025 | Keytruda |
| Inogen, INC. | $77.05 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $49.43 | 2021 | |
| Csl Behring | $48.39 | 2022-2023 | Kcentra |
| Pulmonx Corporation | $44.40 | 2022-2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Avadel Cns Pharmaceuticals, LLC | $43.93 | 2024 | Lumryz |
| Abbvie INC. | $41.98 | 2020-2024 | |
| Advanced Respiratory, INC | $40.49 | 2021 | |
| Azurity Pharmaceuticals, INC. | $40.29 | 2025 | Alvesco |
| Circassia INC. | $38.97 | 2019 | |
| Alk-Abello, INC | $33.10 | 2024 | Ragwitek, Grastek, Odactra |
| Lilly USA, LLC | $32.54 | 2025 | Zepbound |
| Optinose US, INC. | $23.56 | 2022 | |
| Grifols USA, LLC | $23.25 | 2020 | |
| 3b Medical, INC. | $22.69 | 2025 | Luna |
| Phadia US INC. | $21.24 | 2024 | Immunocap |
| Therapeuticsmd, INC. | $20.21 | 2019 | |
| Shire North American Group INC | $17.90 | 2019 | |
| Mallinckrodt Enterprises LLC | $17.66 | 2019 | |
| Hikma Pharmaceuticals USA | $17.38 | 2022 | |
| United Therapeutics Corporation | $14.99 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $13.63 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $11.27 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Russomanno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.